Trump to announce review of vehicle emissions rules:
U.S. President Donald Trump is set to formally announce a review of vehicle fuel efficiency rules locked in at the end of the Obama administration when he meets with automaker chiefs this week, according to two sources briefed on the matter.If you want a Prius, or a Tesla, buy one, but don't make them mandatory.
The move by Trump would be a victory for automakers after months of pushing the new administration to reconsider the rules, which they say would be too expensive, could cost jobs and are out of step with vehicles consumers want to buy.
. . .
Automakers argue the vehicle emissions rules, which would raise the fleet average fuel efficiency to more than 50 miles per gallon (mpg) by 2025 from 27.5 mpg in 2010, will impose significant costs and are out of step with consumer preferences. They argue they need more flexibility to meet the rules amid low gas prices.
President Trump’s FDA nominee could mean better drugs sooner at lower cost
President Trump made an excellent choice on Friday in nominating Dr. Scott Gottlieb to be Commissioner of the Food and Drug Administration. Gottlieb, a medical doctor and former FDA deputy commissioner, knows from experience how FDA’s culture and its ever-increasing demands for more extensive clinical testing delay access to life-saving treatments.Trump to Sign Executive Order Removing "Climate Change" As Factor Government Agencies Regulate
If confirmed, he has an opportunity to shake up a system that has lost sight of what its goal should be — to help patients receive access to better drugs, sooner, at lower cost.
. . .
A mindset focused on greater competition, transparency, feedback and learning could greatly improve patient access to life-enhancing pharmaceuticals. One of us has offered a proposal that holds particular promise, called “Free To Choose Medicine”; it has three key components:
First, a free to choose track would complement FDA’s existing clinical trial track. This would enable patients, advised by their doctors, to contract with a drug developer to use not-yet-approved drugs after Phase I safety trials are successfully completed and one or more Phase II trials have demonstrated continued safety and initial efficacy.
Free-to-choose drugs could be available seven years earlier than the status quo and fundamentally change the economics of drug developmental costs and drug pricing — to the benefit of patients. In this new, fast-paced, competitive environment, many existing drugs, over time, would face heightened competition thereby forcing prices down. A premium would be placed on scientific skill in developing breakthrough medicines, not skill in dealing with the FDA bureaucracy
Second, an open access database, managed by an agency such as the National Institutes of Health, would include up-to-date treatment results for free-to-choose drugs, including patients’ genetic makeup and relevant biomarkers. In addition to offering guidance to patients and doctors, the database would be a treasure trove of insights to guide drug developers in making better R&D decisions.
Third, a new type of drug approval is needed based on treatment results (observational data) for real-world patients who receive free-to-choose drugs. This would utilize advancements in big data analytics, incentivize drug developers to participate in the free-to-choose track, and expedite insurance reimbursements.
I don't know how much Putin paid this guy, but I know I'm getting my money's worth.
Not just the EPA, either.
President Donald Trump is set to sign a sweeping directive to dramatically shrink the role climate change plays in decisions across the government, ranging from appliance standards to pipeline approvals, according to a person familiar with the administration's plan.So knocking out this underlying justification also knocks out a bunch of regulations.
The order, which could be signed this week, goes far beyond a targeted assault on Obama-era measures blocking coal leasing and throttling greenhouse gas emissions from power plants that has been discussed for weeks. Some of the changes could happen immediately; others could take years to implement.
It aims to reverse President Barack Obama's broad approach for addressing climate change. One Obama-era policy instructed government agencies to factor climate change into formal environmental reviews, such as that for the Keystone XL pipeline. Trump's order also will compel a reconsideration of the government's use of a metric known as the "social cost of carbon" that reflects the potential economic damage from climate change. It was used by the Obama administration to justify a suite of regulations.